Monoclonal gammopathy of undetermined significance classification
|
Monoclonal gammopathy of undetermined significance Microchapters |
|
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Monoclonal gammopathy of undetermined significance classification On the Web |
|
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance classification |
|
FDA on Monoclonal gammopathy of undetermined significance classification |
|
on Monoclonal gammopathy of undetermined significance classification |
|
Monoclonal gammopathy of undetermined significance classification in the news |
|
Blogs on Monoclonal gammopathy of undetermined significance classification |
|
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2] Muhammad Saad, M.B.B.S.[3]
Overview
Monoclonal gammopathy of undetermined significance (MGUS) may be classified according to cytogenetic differences into subtypes/groups based on translocations. There is no established system for the staging of monoclonal gammopathy of undetermined significance (MGUS).
Classification
MGUS is typically divided into non-IgM MGUS, IgM MGUS, and light chain MGUS as described in the following flowchart:[1][2][3][4]
| Non IgM MGUS: 1. <10%BM plasma cells 2. Monoclonal protein <3.0g/dL 3. No symptoms | Smoldering MM: 1. No symptoms 2. >10%BM plasma cells | MM: 1. Symptoms 2. >10%BM plasma cells AL Amyloidosis | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| IgM MGUS: 1. <10%BM lymphoplasmacytic cells 2. Monoclonal protein <3.0g/dL 3. No symptoms | Smoldering WM: 1. No symptoms 2. >10%BM lymphoplasmacytic cells | WM: 1. Symptoms 2. >10%BM lymphoplasmacytic cells AL Amyloidosis IgM MM | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clonal plasma cell or B lymphocyte | Light chain MGUS: 1. <10%BM plasma cells 2. Abnormal FLC ratio 3. No monoclonal protein 4. No symptoms | Light chain MM: 1. Symptoms 2. >10%BM plasma cells AL Amyloidosis | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Monoclonal gammopathy of clinical significance : 1. Presence of monoclonal protein or FLC 2. Symptoms attributable to presence of monoclonal protein 3. Diagnostic criteria of MM not met | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Monoclonal gammopathy of undetermined significance (MGUS) may be classified according to cytogenetic differences into the following subtypes/groups:[5]
| Abnormalities in cytogenes | Affected genes |
| IgH translocation: | |
| t(11;14), q(13;32) | cyclin D1 |
| t(4;14)(p16;q32) | FGFR-3, and MMSET |
| t(14;16)(q32;q23) | C-MAF |
| t(6;14)(q32;q11) | MAFB |
| IgH non-translocated : | |
| Hyper diploid | Numerous |
References
- ↑ Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (November 2014). "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma". Lancet Oncol. 15 (12): e538–48. doi:10.1016/S1470-2045(14)70442-5. PMID 25439696.
- ↑ Gertz MA (February 2023). "Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management". Am J Hematol. 98 (2): 348–358. doi:10.1002/ajh.26796. PMID 36588395 Check
|pmid=value (help). - ↑ Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M (June 2010). "Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management". Leukemia. 24 (6): 1121–7. doi:10.1038/leu.2010.60. PMC 7020664 Check
|pmc=value (help). PMID 20410922. - ↑ Gertz MA, Dispenzieri A (July 2020). "Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review". JAMA. 324 (1): 79–89. doi:10.1001/jama.2020.5493. PMID 32633805 Check
|pmid=value (help). - ↑ Rajkumar SV, Kyle RA, Buadi FK (October 2010). "Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence". Mayo Clin. Proc. 85 (10): 945–8. doi:10.4065/mcp.2010.0520. PMC 2947967. PMID 20884827.